Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosmir
- Development stage
- Phase 3
- Lead developer
- Cutigen Research Institute
- Modality
- Cell Therapies
- Administration
- Intradermal
01
Overview
**Rosmir** is an autologous fibroblast cell therapy product approved in Korea for improving moderate to severe nasojugal grooves (tear trough deformities). It consists of cultured fibroblasts derived from a patient's own skin biopsy, which are expanded over 3-6 weeks and injected back into the dermal layer to stimulate collagen production, cytokine secretion, and dermal cell proliferation, thereby restoring skin structure and reducing wrinkles. Developed and manufactured by Tego Science, it represents the world's first approved cell therapy specifically for this cosmetic indication by the MFDS in 2017.
- Brand names
- Rosmir
Beyond the preview
Go deeper on Rosmir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rosmir.